%0 Journal Article
%T Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
%A Elizabeth Wu
%A Ivar S. Jensen
%A Karen C. Chung
%A Naomi C. Sacks
%A Philip L. Cyr
%J Archive of "American Health & Drug Benefits".
%D 2018
%X Current national estimates for acute myelogenous leukemia (AML) indicate this disease accounts for 1.1% of new cancer diagnoses and 1.8% of cancer deaths in the United States. The 5-year overall survival rate for patients with AML was 27.4% between 2008 and 2014. The standard induction for patients with AML includes cytarabine, infused for 7 days, with 3 once-daily injections of an anthracycline, such as daunorubicin, known as the 7+3 regimen. Daunorubicin plus cytarabine liposomal encapsulation for injection was approved in the United States in 2017 for adults with newly diagnosed therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC)
%K acute myelogenous leukemia
%K AML with myelodysplasia-related changes
%K budget impact
%K daunorubicin-cytarabine liposome
%K incremental cost
%K 7+3 regimen
%K tAML
%K therapy-related AML
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306103/